Elias H. Cohen - Related publications

Affiliations: 
Vanderbilt University, Nashville, TN 
Website:
http://www.psy.vanderbilt.edu/tonglab/testing/elias/Home.html
NOTE: We are testing a new system for identifying relevant work based on semantic analysis that identifies similarities between recently published papers and the current author's publications. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches.
50 most relevant papers in past 60 days:
Year Citation  Score
2020 Shin MH, Kim J, Lim SA, Kim J, Lee KM. Current Insights into Combination Therapies with MAPK Inhibitors and Immune Checkpoint Blockade. International Journal of Molecular Sciences. 21. PMID 32260561 DOI: 10.3390/ijms21072531   
2020 Shen FF, Guo W, Tian RF, Guo Y, Yang YL, Song X. Long-term survival with targeted therapy in an advanced non-small cell lung cancer patient based on genetic profiling. Translational Lung Cancer Research. 9: 373-378. PMID 32420078 DOI: 10.21037/tlcr.2020.01.21   
2020 Liang J, Chen D, Chen L, She X, Zhang H, Xiao Y. The potentiality of immunotherapy for sarcomas: a summary of potential predictive biomarkers. Future Oncology (London, England). PMID 32396026 DOI: 10.2217/fon-2020-0118   
2020 Miura N, Matsubara T, Takamori S, Haratake N, Toyozawa R, Yamaguchi M, Seto T, Taguchi K, Takenoyama M. Histological conversion from adenocarcinoma to small cell carcinoma of the lung after treatment with an immune checkpoint inhibitor: a case report. Oxford Medical Case Reports. 2020: omaa026. PMID 32477576 DOI: 10.1093/omcr/omaa026   
2020 Cheng C, Zhao Y, Schaafsma E, Weng YL, Amos C. An EGFR signature predicts cell line and patient sensitivity to multiple tyrosine kinase inhibitors. International Journal of Cancer. PMID 32406930 DOI: 10.1002/ijc.33053   
2020 Jones SF, McKenzie AJ. Molecular Profiling in Drug Development: Paving a Way Forward. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 40: 309-318. PMID 32463698 DOI: 10.1200/EDBK_100024   
2020 Kiss I, Kolostova K, Pawlak I, Bobek V. Circulating tumor cells in gynaecological malignancies. Journal of B.U.On. : Official Journal of the Balkan Union of Oncology. 25: 40-50. PMID 32277613   
2020 Chiang AC, Fernandes AW, Pavilack M, Wu JW, Laliberté F, Duh MS, Chehab N, Subramanian J. EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors. Bmc Cancer. 20: 356. PMID 32345265 DOI: 10.1186/s12885-020-06826-0   
2020 Kirtonia A, Sethi G, Garg M. The multifaceted role of reactive oxygen species in tumorigenesis. Cellular and Molecular Life Sciences : Cmls. PMID 32358622 DOI: 10.1007/s00018-020-03536-5   
2020 Hulo P, Coupez D, Denis M, Bennouna J. EGFR mutation-positive NSCLC: factors to consider when deciding first-line therapy. Expert Review of Anticancer Therapy. PMID 32302244 DOI: 10.1080/14737140.2020.1757439   
2020 Chen C, Cheng CD, Wu H, Wang ZW, Wang L, Jiang ZR, Wang AL, Hu C, Dong YF, Niu WX, Qi S, Qi ZP, Liu J, Wang WC, Niu CS, et al. Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway. Acta Pharmacologica Sinica. PMID 32398685 DOI: 10.1038/s41401-020-0418-2   
2020 Raninga PV, Lee A, Sinha D, Dong LF, Datta KK, Lu X, Kalita-de Croft P, Dutt M, Hill M, Pouliot N, Gowda H, Kalimutho M, Neuzil J, Khanna KK. Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition. Theranostics. 10: 5259-5275. PMID 32373211 DOI: 10.7150/thno.42705   
2020 Allam M, Cai S, Coskun AF. Multiplex bioimaging of single-cell spatial profiles for precision cancer diagnostics and therapeutics. Npj Precision Oncology. 4: 11. PMID 32377572 DOI: 10.1038/s41698-020-0114-1   
2020 Friedrich M, Wiedemann K, Reiche K, Puppel SH, Pfeifer G, Zipfel I, Binder S, Köhl U, Müller GA, Engeland K, Aigner A, Füssel S, Fröhner M, Peitzsch C, Dubrovska A, et al. The Role of lncRNAs TAPIR-1 and -2 as Diagnostic Markers and Potential Therapeutic Targets in Prostate Cancer. Cancers. 12. PMID 32365858 DOI: 10.3390/cancers12051122   
2020 Cirauqui B, Morán T, Estival A, Quiroga V, Etxaniz O, Balana C, Navarro M, Villà S, Ballester R, Margelí M. Breast Cancer Patient with Li-Fraumeni Syndrome: A Case Report Highlighting the Importance of Multidisciplinary Management. Case Reports in Oncology. 13: 130-138. PMID 32231534 DOI: 10.1159/000505684   
2020 Galiana I, Lozano-Torres B, Sancho M, Alfonso M, Bernardos A, Bisbal V, Serrano M, Martínez-Máñez R, Orzáez M. Preclinical antitumor efficacy of senescence-inducing chemotherapy combined with a nanoSenolytic. Journal of Controlled Release : Official Journal of the Controlled Release Society. 323: 624-634. PMID 32376460 DOI: 10.1016/j.jconrel.2020.04.045   
2020 Hsu ML, Naidoo J. Principles of Immunotherapy in Non-Small Cell Lung Cancer. Thoracic Surgery Clinics. 30: 187-198. PMID 32327177 DOI: 10.1016/j.thorsurg.2020.01.009   
2020 Cabrita R, Mitra S, Sanna A, Ekedahl H, Lövgren K, Olsson H, Ingvar C, Isaksson K, Lauss M, Carneiro A, Jönsson G. The Role of PTEN Loss in Immune Escape, Melanoma Prognosis and Therapy Response. Cancers. 12. PMID 32245160 DOI: 10.3390/cancers12030742   
2020 Min KW, Kim WS, Kim DH, Son BK, Oh YH, Kwon MJ, Lee HS, Lee SE, Kim IA, Moon JY, Kim KY, Park JH. High polymerase ε expression associated with increased CD8+T cells improves survival in patients with non-small cell lung cancer. Plos One. 15: e0233066. PMID 32433714 DOI: 10.1371/journal.pone.0233066   
2020 Terraneo N, Jacob F, Dubrovska A, Grünberg J. Novel Therapeutic Strategies for Ovarian Cancer Stem Cells. Frontiers in Oncology. 10: 319. PMID 32257947 DOI: 10.3389/fonc.2020.00319   
2020 Dodson C, Richards TJ, Smith DA, Ramaiya NH. Tyrosine Kinase Inhibitor Therapy for Brain Metastases in Non-Small-Cell Lung Cancer: A Primer for Radiologists. Ajnr. American Journal of Neuroradiology. PMID 32217548 DOI: 10.3174/ajnr.A6477   
2020 Wang W, Bai L, Xu D, Li W, Cui J. Immunotherapy: A Potential Approach to Targeting Cancer Stem Cells. Current Cancer Drug Targets. PMID 32364076 DOI: 10.2174/1568009620666200504111914   
2020 Wang L, Qin W, Huo YJ, Li X, Shi Q, Rasko JEJ, Janin A, Zhao WL. Advances in targeted therapy for malignant lymphoma. Signal Transduction and Targeted Therapy. 5: 15. PMID 32296035 DOI: 10.1038/s41392-020-0113-2   
2020 Khan KA, Kerbel RS. A new Tie1 targeted antibody blocks tumor cell extravasation and metastasis. Embo Molecular Medicine. e12355. PMID 32406209 DOI: 10.15252/emmm.202012355   
2020 Yin WM, Li YW, Gu YQ, Luo M. Nanoengineered targeting strategy for cancer immunotherapy. Acta Pharmacologica Sinica. PMID 32398683 DOI: 10.1038/s41401-020-0417-3   
2020 Yin L, Xia Y, Xu P, Zheng W, Gao Y, Xie F, Ji Z. Veratramine suppresses human HepG2 liver cancer cell growth in vitro and in vivo by inducing autophagic cell death. Oncology Reports. PMID 32468056 DOI: 10.3892/or.2020.7622   
2020 Buder A, Hochmair MJ, Setinek U, Pirker R, Filipits M. mutation tracking predicts survival in advanced -mutated non-small cell lung cancer patients treated with osimertinib. Translational Lung Cancer Research. 9: 239-245. PMID 32420063 DOI: 10.21037/tlcr.2020.03.02   
2020 Stefansson OA, Hilmarsdottir H, Olafsdottir K, Tryggvadottir L, Sverrisdottir A, Johannsson OT, Jonasson JG, Eyfjord JE, Sigurdsson S. Promoter Methylation Status in 1031 Primary Breast Cancers Predicts Favorable Outcomes Following Chemotherapy. Jnci Cancer Spectrum. 4: pkz100. PMID 32175521 DOI: 10.1093/jncics/pkz100   
2020 Tsimberidou AM, Fountzilas E, Nikanjam M, Kurzrock R. Review of precision cancer medicine: Evolution of the treatment paradigm. Cancer Treatment Reviews. 86: 102019. PMID 32251926 DOI: 10.1016/j.ctrv.2020.102019   
2020 Cai S, Allam M, Coskun AF. Multiplex Spatial Bioimaging for Combination Therapy Design. Trends in Cancer. PMID 32466969 DOI: 10.1016/j.trecan.2020.05.003   
2020 Rasmussen CM, Lee SKY, Arce K, Salinas TJ. Interdisciplinary rehabilitation of a primary intraosseous carcinoma including orthodontic archform management. Quintessence International (Berlin, Germany : 1985). 2-10. PMID 32368764 DOI: 10.3290/j.qi.a44494   
2020 Lin X, Liao J, Geng X, Dan H, Chen L. Concurrent inhibition of ErbB family and MEK/ERK kinases to suppress non-small cell lung cancer proliferation. American Journal of Translational Research. 12: 847-856. PMID 32269717   
2020 Lin TC. is Epigenetically Repressed in Renal Cell Carcinoma and Serves as a Prognostic Indicator and Therapeutic Target in Cancer Progression. International Journal of Molecular Sciences. 21. PMID 32326089 DOI: 10.3390/ijms21082881   
2020 Wang S, Zhang J, Meng FJ, Yan YJ, Wang B, Guan ZY. Combination of pembrolizumab and I attenuates the aggressiveness of non-small cell lung cancer. Oncology Letters. 19: 4142-4150. PMID 32382353 DOI: 10.3892/ol.2020.11508   
2020 Li G, Tong X, Pan L, Huang H, Ma H, Feng Y. Epididymal protein 3A is upregulated and promotes cell proliferation in non-small cell lung cancer. Oncology Letters. 19: 4024-4030. PMID 32391105 DOI: 10.3892/ol.2020.11517   
2020 Ma R, Mandell J, Lu F, Heim T, Schoedel K, Duensing A, Watters RJ, Weiss KR. Do Patient-derived Spheroid Culture Models Have Relevance in Chondrosarcoma Research? Clinical Orthopaedics and Related Research. PMID 32469486 DOI: 10.1097/CORR.0000000000001317   
2020 Gough MJ, Sharon S, Crittenden MR, Young KH. Using Preclinical Data to Design Combination Clinical Trials of Radiation Therapy and Immunotherapy. Seminars in Radiation Oncology. 30: 158-172. PMID 32381295 DOI: 10.1016/j.semradonc.2019.12.002   
2020 Hempel D, Wieland T, Solfrank B, Grossmann V, Steinhard J, Frick A, Hempel L, Eberl T, Gaumann A. Antitumor Activity of Larotrectinib in Esophageal Carcinoma with NTRK Gene Amplification. The Oncologist. PMID 32323889 DOI: 10.1634/theoncologist.2019-0641   
2020 Janke F, Bozorgmehr F, Wrenger S, Dietz S, Heussel CP, Heussel G, Silva CF, Rheinheimer S, Feisst M, Thomas M, Golpon H, Günther A, Sültmann H, Muley T, Janciauskiene S, et al. Novel Liquid Biomarker Panels for A Very Early Response Capturing of NSCLC Therapies in Advanced Stages. Cancers. 12. PMID 32290637 DOI: 10.3390/cancers12040954   
2020 Chalabi M, Fanchi LF, Dijkstra KK, Van den Berg JG, Aalbers AG, Sikorska K, Lopez-Yurda M, Grootscholten C, Beets GL, Snaebjornsson P, Maas M, Mertz M, Veninga V, Bounova G, Broeks A, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nature Medicine. PMID 32251400 DOI: 10.1038/s41591-020-0805-8   
2020 Yan M, Wang W, Zhou J, Chang M, Peng W, Zhang G, Li J, Li H, Bai C. Knockdown of enhances the anticancer effect of gefitinib in non-small cell lung cancer. Journal of Thoracic Disease. 12: 712-723. PMID 32274137 DOI: 10.21037/jtd.2019.12.106   
2020 Wen P, Gao Y, Chen B, Qi X, Hu G, Xu A, Xia J, Wu L, Lu H, Zhao G. Pan-Cancer Analysis of Radiotherapy Benefits and Immune Infiltration in Multiple Human Cancers. Cancers. 12. PMID 32294976 DOI: 10.3390/cancers12040957   
2020 Muñoz-Galván S, Rivero M, Peinado-Serrano J, Martinez-Pérez J, Fernández-Fernández MC, Ortiz MJ, García-Heredia JM, Carnero A. PAI1 is a Marker of Bad Prognosis in Rectal Cancer but Predicts a Better Response to Treatment with PIM Inhibitor AZD1208. Cells. 9. PMID 32344898 DOI: 10.3390/cells9051071   
2020 Muñoz-Galván S, Rivero M, Peinado-Serrano J, Martinez-Pérez J, Fernández-Fernández MC, Ortiz MJ, García-Heredia JM, Carnero A. PAI1 is a Marker of Bad Prognosis in Rectal Cancer but Predicts a Better Response to Treatment with PIM Inhibitor AZD1208. Cells. 9. PMID 32344898 DOI: 10.3390/cells9051071   
2020 Joseph JF, Gronbach L, García-Miller J, Cruz LM, Wuest B, Keilholz U, Zoschke C, Parr MK. Automated Real-Time Tumor Pharmacokinetic Profiling in 3D Models: A Novel Approach for Personalized Medicine. Pharmaceutics. 12. PMID 32366029 DOI: 10.3390/pharmaceutics12050413   
2020 Joseph JF, Gronbach L, García-Miller J, Cruz LM, Wuest B, Keilholz U, Zoschke C, Parr MK. Automated Real-Time Tumor Pharmacokinetic Profiling in 3D Models: A Novel Approach for Personalized Medicine. Pharmaceutics. 12. PMID 32366029 DOI: 10.3390/pharmaceutics12050413   
2020 Li KS, Zhu XD, Liu HD, Zhang SZ, Li XL, Xiao N, Liu XF, Xu B, Lei M, Zhang YY, Shi WK, Cao MQ, Xu YF, Tang ZY, Sun HC. NT5DC2 promotes tumor cell proliferation by stabilizing EGFR in hepatocellular carcinoma. Cell Death & Disease. 11: 335. PMID 32382041 DOI: 10.1038/s41419-020-2549-2   
2020 Giustini NP, Jeong AR, Buturla J, Bazhenova L. Advances in Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Targeted Therapy. Clinics in Chest Medicine. 41: 223-235. PMID 32402358 DOI: 10.1016/j.ccm.2020.02.003   
2020 Wang H, Xu P, Sun G, Lv J, Cao J, Xu Z. Downregulation of PHF19 inhibits cell growth and migration in gastric cancer. Scandinavian Journal of Gastroenterology. 1-7. PMID 32449434 DOI: 10.1080/00365521.2020.1766555   
2020 Dianat-Moghadam H, Azizi M, Eslami-S Z, Cortés-Hernández LE, Heidarifard M, Nouri M, Alix-Panabières C. The Role of Circulating Tumor Cells in the Metastatic Cascade: Biology, Technical Challenges, and Clinical Relevance. Cancers. 12. PMID 32260071 DOI: 10.3390/cancers12040867